Results 51 to 60 of about 306 (142)

Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study

Cancer Science, Volume 116, Issue 1, Page 248-256, January 2025.
We constructed a lung cancer detection model using four circulating free DNA (cfDNA) fragmentation features, and this model exhibits strong screening capabilities. It is not only effective for early cancer screening in asymptomatic individuals but also demonstrates robust detection capabilities in early cancer diagnosis.
Fudong Xu, Chong Wang, Hongxia Li, Bo Yu, Luyuan Chang, Feng Wang, Chaolian Long, Ling Bai, Hanqing Zhao, Nanying Che   +9 more
wiley   +1 more source

EHA2021 Virtual Congress Abstract Book

, 2021
HemaSphere, Volume 5, Issue S2, June 2021.
wiley   +1 more source

Transformer‐based representation learning and multiple‐instance learning for cancer diagnosis exclusively from raw sequencing fragments of bisulfite‐treated plasma cell‐free DNA

Molecular Oncology, Volume 18, Issue 11, Page 2755-2769, November 2024.
This study introduces DECIDIA, a deep‐learning approach for early cancer diagnosis using bisulfite‐treated cfDNA sequencing fragments. Utilizing transformer‐based representation learning and weakly supervised multiple‐instance learning, DECIDIA accurately detects cancer and predicts cancer types, significantly simplifying data analysis.
Jilei Liu, Hongru Shen, Yichen Yang, Meng Yang, Qiang Zhang, Kexin Chen, Xiangchun Li   +6 more
wiley   +1 more source

Plasma Cell‐Free DNA Concentration and Fragmentomes Predict Neoadjuvant Chemotherapy Response in Cervical Cancer Patients

Advanced Science, Volume 11, Issue 43, November 20, 2024.
Cervical cancer patients with varying responses to neoadjuvant chemotherapy (NACT) exhibit unique patterns of variation in cell‐free DNA (cfDNA) levels and fragmentomic characteristics. The cfDNA emerges as a promising biomarker for predicting tumor response to NACT in cervical cancer, offering a novel approach for monitoring treatment response to ...
Ting Peng, Haiqiang Zhang, Lingguo Li, Canhui Cao, Miaochun Xu, Xiaojie Liu, Shitong Lin, Ping Wu, Tian Chu, Binghan Liu, Yashi Xu, Yan Zhang, Yeqin Wang, Jinjin Yu, Wencheng Ding, Xin Jin, Peng Wu   +16 more
wiley   +1 more source

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges

MedComm, Volume 5, Issue 11, November 2024.
The origin of ctDNA in the bloodstream is derived from CTC, exosomes secreted by tumor cells, apoptotic tumor cells and necrotic tumor cells (A). ctDNA methylation status plays an important role in the occurrence and development of cancer and is a biomarker for tumor liquid biopsy.
Lingyu Li, Yingli Sun
wiley   +1 more source

Circulating Cell-free DNA Fragmentomics Detection and Beyond

aging and disease
Circulating cell-free DNA (cfDNA) comprises DNA fragments released into bodily fluids via apoptosis, necrosis, or phagocytosis. cfDNA encapsulates both fragmentomics (structural) and non-fragmentomics (sequence/epigenetic) information from source cells, thereby representing a promising biomarker.
Tianliang, Liu, Zhicheng, Li, Shifu, Chen, Jiasheng, Zhong   +3 more
openaire   +2 more sources

Advances in early detection of non‐small cell lung cancer: A comprehensive review

Cancer Medicine, Volume 13, Issue 18, September 2024.
Abstract Background Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and ...
Nour Kenaan, George Hanna, Moustafa Sardini, Mhd Omar Iyoun, Khedr Layka, Zein Alabdin Hannouneh, Zuheir Alshehabi   +6 more
wiley   +1 more source

Cell-free DNA fragmentomics for preeclampsia risk assessment

Nature Communications
Abstract Preeclampsia (PE) is a pregnancy-specific hypertensive disorder that could lead to serious maternal and fetal complications, yet early identification of women at risk remains challenging because reliable biomarkers are limited.
Wenqiu Xu, Songchang Chen, Jia Li, Si Zhou, Yanning Yin, Zhixu Qiu, Jianguo Zhang, Cong Liu, Qiang Zhao, Gefei Xiao, Yan Zhou, Zhiguang Zhao, Xiao Zhang, Wenzhi Yang, Yunfang Wang, Huiqin Li, Zhen Yang, Suihua Feng, Qun Zhang, Weiping Chen, Huahua Li, Xiaohong Ruan, Hua Li, Sufen Zhang, Liqing Hu, Jie Qin, Wuyan Huang, Zhongzhe Li, Xianling Cao, Xuanyou Zhou, Naixin Xu, Dongxia Hou, Hong Dong, Jie Wang, Yaxian Liu, Quanfu Zhang, Xiaohua Wang, Lijian Zhao, Hefeng Huang, Chenming Xu   +39 more
openaire   +1 more source

Cell-Free DNA Fragmentomics: The New “Omics” on the Block [PDF]

Clinical Chemistry, 2020
Rossa W K Chiu, Ellen Heitzer, Y M Dennis Lo, Florent Mouliere, Dana W Y Tsui   +4 more
openaire   +1 more source

Quantitative fragmentome mapping reveals novel, domain-specific partners for the modular protein repoMan (recruits PP1 onto mitotic chromatin at anaphase) [PDF]

, 2013
RepoMan is a protein phosphatase 1 (PP1) regulatory subunit that targets the phosphatase to key substrates throughout the cell cycle. Most work to date has focused on the mitotic roles of RepoMan/PP1, although equally important interphase role(s) have ...
Trinkle-Mulcahy, L., Moorhead, G., Nasa, I., Freele, E., Prevost, M., Chamousset, D., Morrice, N.   +6 more
core   +1 more source